| Identification | Back Directory | [Name]
Idazoxan | [CAS]
79944-58-4 | [Synonyms]
Idazoxan
Idezoxane
RX-781094
dl-Idazoxan
IDAZOXAN,99%
RaceMic idazoxan
1,4-Benzodioxin, 1H-iMidazole deriv.
2-(1-Imidazoline-2-yl)-2,3-dihydro-1,4-benzodioxin
2-(2-Imidazoline-2-yl)-2,3-dihydro-1,4-benzodioxin
2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole
2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole
1H-IMidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro- | [Molecular Formula]
C11H12N2O2 | [MOL File]
79944-58-4.mol | [Molecular Weight]
204.23 |
| Hazard Information | Back Directory | [Uses]
alpha2-adrenergic blocker | [Definition]
ChEBI: A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group. | [Metabolic pathway]
When rats are administered radio-labeled idazoxan
orally, the biotransformation of idazoxan is by
hydroxylation at the 6- and 7-positions to form
phenolic metabolites, which are excreted as
glucuronide and sulfate metabolites in the urine, but
unconjugated in the feces. Other minor metabolic
pathways are 5-hydroxylation or oxidative degradation
of the imidazoline ring, but these pathways are of
quantitatively minor importance in rats. |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|